Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125793171 | 12579317 | 1 | I | 20160509 | 20160713 | 20160721 | 20160721 | EXP | FR-JNJFOC-20160710587 | PHARMACYCLICS | 80.09 | YR | E | F | Y | 0.00000 | 20160721 | CN | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125793171 | 12579317 | 1 | SS | IMBRUVICA | IBRUTINIB | 1 | Oral | N | 0 | CAPSULE | |||||||||
| 125793171 | 12579317 | 2 | PS | IMBRUVICA | IBRUTINIB | 1 | Oral | N | 205552 | CAPSULE | |||||||||
| 125793171 | 12579317 | 3 | SS | MABTHERA | RITUXIMAB | 1 | Subcutaneous | 0 | UNSPECIFIED | ||||||||||
| 125793171 | 12579317 | 4 | SS | MABTHERA | RITUXIMAB | 1 | Subcutaneous | 0 | UNSPECIFIED | ||||||||||
| 125793171 | 12579317 | 5 | SS | ALDARA | IMIQUIMOD | 1 | Topical | 1DOSE/DAY | 0 | 1 | DF | CREAM | |||||||
| 125793171 | 12579317 | 6 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 0 | UNSPECIFIED | ||||||||||
| 125793171 | 12579317 | 7 | SS | ZELITREX | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | 0 | UNSPECIFIED | ||||||||||
| 125793171 | 12579317 | 8 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Unknown | 0 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125793171 | 12579317 | 1 | Lymphoma |
| 125793171 | 12579317 | 2 | Mantle cell lymphoma |
| 125793171 | 12579317 | 3 | Lymphoma |
| 125793171 | 12579317 | 4 | Mantle cell lymphoma |
| 125793171 | 12579317 | 5 | Skin lesion |
| 125793171 | 12579317 | 6 | Product used for unknown indication |
| 125793171 | 12579317 | 7 | Product used for unknown indication |
| 125793171 | 12579317 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125793171 | 12579317 | DE |
| 125793171 | 12579317 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125793171 | 12579317 | Diarrhoea | |
| 125793171 | 12579317 | Dizziness | |
| 125793171 | 12579317 | Dry mouth | |
| 125793171 | 12579317 | Fatigue | |
| 125793171 | 12579317 | Headache | |
| 125793171 | 12579317 | Insomnia | |
| 125793171 | 12579317 | Nausea | |
| 125793171 | 12579317 | Seizure | |
| 125793171 | 12579317 | Tinnitus |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125793171 | 12579317 | 1 | 201505 | 0 | ||
| 125793171 | 12579317 | 2 | 201505 | 0 | ||
| 125793171 | 12579317 | 3 | 201503 | 0 | ||
| 125793171 | 12579317 | 4 | 201503 | 0 | ||
| 125793171 | 12579317 | 5 | 20160503 | 20160524 | 0 |